Identifying Critical Factors Pre-launch
|
|
- Reginald Stanley
- 6 years ago
- Views:
Transcription
1 Identifying Critical Factors Pre-launch Incorporate pricing and market access into product planning Eric M. Bachman, Director Boston office One Canal Park Cambridge, MA 02141, USA Tel
2 Simon-Kucher is a leading management consultancy >2,000 projects in the last 3 years Global presence Strategy > 400 Sales > 500 Marketing > 500 Pricing > 1,000 Growth and competitive strategies Product portfolio (re-)design Pricing excellence Customer relationship and customer value management Sales strategies and sales channel optimization Toronto Boston New York San Francisco Atlanta Amsterdam Madrid Barcelona Milan Dubai Bonn Munich Brussels Paris Cologne Warsaw São Paulo Copenhagen Vienna Frankfurt Zurich Santiago de Chile Istanbul London Luxembourg 29 offices worldwide, 800 employees Beijing Singapore Tokyo Sydney Simon-Kucher s revenue split Simon-Kucher s growth Other Revenue in $m No. of Employees Chemicals/ Construction Automotive 7% 10% 13% 35% Healthcare Pharma MedTech Biotech Providers Technology/ Engineering 11% Financial Services 12% 12% Telco/IT/Media '00 '05 '10 '11 '12 ' '95 '00 '05 '10 '11 '12 '13 '14 Source: Simon-Kucher 2
3 We are recognized as the world s leading pricing advisor Unrivalled experience World leader in pricing 2,000+ Pricing projects completed in the last 3 years alone World leader in giving advice to companies on how to price their products BusinessWeek The world s leading pricing consultancy The Economist 800 Strategy professionals in 29 offices worldwide Pricing strategy specialists The Wall Street Journal In pricing you offer something nobody else does Professor Peter Drucker Best consultancies in marketing and sales* 1 to 5 % Percentage points on margin improvement 1 Simon-Kucher & Partners manager magazin 40 Books written on pricing and business management 2 3 Boston Consulting Group McKinsey & Company Source: manager magazine, August 2011/IMB, survey among German top managers 3
4 Agenda Why worry about P&MA during development? What factors should be considered and when? Evaluating the risk vs reward trade-off 4
5 Case study 1: Product s positioning in the therapeutic pathway can drastically change its price potential Product Example High risk Potentially infected Severely symptomatic Patients that are not showing signs of infection The infection is not confirmed, but some symptoms are shown Patients are confirmed to be infected and become much more difficult to treat Patient population Unmet need and willingness to pay Situation: Phase 1 product Treats a rare type of hospital infection Client has questions about price, value, and access Problem: The transition to severely symptomatic only takes 1-2 days and makes the infection much more difficult to treat Willingness to pay is low until the infection worsens significantly Solution: Position the product where willingness to pay is high but at a point before the infection became difficult to treat 5
6 Case study 2: Product s clinical design may not be accepted by payers for reimbursement For a product that was starting phase 3 trials, the market needs had changed substantially. Product Example BMD Comparator data Fracture data Regulatory requirements Reimbursement requirements Payers were likely to require multiple lines of therapy before using the new agent with the planned data package Differences between US and EU needs made the situation more complex There were questions about the validity of the BMD endpoint with KOLs After a thorough evaluation, the manufacturer decided to not continue developing the therapy. 6
7 Pricing & market access input in development stage leads to big payoffs (slide o summarize the importance and need for early P&MA) Typical product cash flow: Product cash flow Product Revenues R&D Costs Cash flow with P&MA planning across development stages: 1 Reduces costs by: Prioritizing R&D candidates based on future potential Making quicker and better go / no go decisions 2 3 Increases incremental peak revenue: gains compound year-on-year Accelerates revenue: payerrationalized clinical trials lead to faster reimbursement Clinical development stage Source: Simon-Kucher & Partners 7
8 Agenda Why worry about P&MA during development? What factors should be considered and when? Evaluating the risk vs reward trade-off 8
9 Simon-Kucher recommends the payer perspective be built into all junctures in a product s lifecycle Typical focus areas during a product s lifecycle Start of... Phase I trials Start of... Phase II trials Start of... Phase III Trials Launch Strategic R&D Landscape and initial pricing assessment Market access launch pricing strategy & contracting options Value strategy framework Development of value proposition framework Value story development and positioning Landscape assessment Mock payer negotiations Payer-rationalized clinical trial design Market access playbooks LOE planning Focus: Price-positioning Focus: P&MA strategy Source: Simon-Kucher & Partners. 9
10 Simon-Kucher recommends the payer perspective be built into all junctures in a product s lifecycle Typical focus areas during a product s lifecycle Start of... Phase I trials Start of... Phase II trials Start of... Phase III Trials Launch Strategic R&D Landscape and initial pricing assessment Market access launch pricing strategy & contracting options Value strategy framework Development of value proposition framework Value story development and positioning Landscape assessment Mock payer negotiations Payer-rationalized clinical trial design Market access playbooks LOE planning Focus: Price-positioning Focus: P&MA strategy Source: Simon-Kucher & Partners 10
11 Price-positioning: questions to consider How will the market change before the product launches? What product benefits are needed to achieve commercial success? How can we design a development program that will meet the needs of regulators, physicians, and payers? How does the strategy for this product fit into the broader organizational mission/goals/objectives/strategy? Source: Simon-Kucher & Partners. 11
12 The design and outcomes of clinical trials will have a major influence on a product s perceived value Stakeholder assessment of the clinical trial design and the expected outcomes helps to shape the product s future market access and pricing strategy. What information is meaningful to stakeholders? How do different development scenarios influence perceived value and P&R opportunities? What are lessons learned from comparable products? How do payers and physicians value the clinical trial design and comparators? Which primary and secondary endpoints provide strongest evidence? Clinical trials for a new drug Is data necessary for specific patient subpopulations? What is the value of patient- and physician- reported outcomes? What influence do the duration & size of the trial have? Perceived therapeutic improvement Use & market uptake Reimbursement & market access Pricing opportunities Source: Simon-Kucher & Partners. 12
13 From an access perspective, how do we prioritize indications? The market access potential can vary substantially across markets. Project Example Overall attractiveness US Overall attractiveness EU-4 (DE, FR, IT, SP) High Maybe Strong negotiation position Go Maybe Strong negotiation position Go Bubble size (relative mkt size) should be compared within each graph, not across graphs. Indication 1 Indication 2 Indication 1 KOL demand Indication 2 Indication 3 Indication 3 Low No go Weak negotiation position Weak competitive position No go Weak negotiation position Weak competitive position Not covered Covered with restrictions Covered Not reimbursed Reimbursed with restrictions Reimbursed Coverage at current price Reimbursement at current price Bubble size factors in eligible patient population and treatment duration. Source: Simon-Kucher & Partners. Data has been disguised 13
14 Even early in development, a concept for the value story can be developed Value story Target value proposition A short, concise statement to communicate the value of the product to key stakeholders Early in development, there may be a single product statement Key value messages Summary of key points of value story Detailed evidence and supporting data Detailed presentation of supporting evidence An effective value story needs to: Support the overall product and portfolio strategies Target payers as well as other stakeholders access drivers & incentives Address the questions for which payers & other stakeholders want answers Source: Simon-Kucher & Partners 14
15 Simon-Kucher recommends the payer perspective be built into all junctures in a product s lifecycle Typical focus areas during a product s lifecycle Start of... Phase I trials Start of... Phase II trials Start of... Phase III Trials Launch Strategic R&D Landscape and initial pricing assessment Market access launch pricing strategy & contracting options Value strategy framework Development of value proposition framework Value story development and positioning Landscape assessment Mock payer negotiations Payer-rationalized clinical trial design Market access playbooks LOE planning Focus: Price-positioning Focus: P&MA strategy Source: Simon-Kucher & Partners 15
16 P&MA strategy: questions to consider $ What price at launch would optimize access and revenue? How can we effectively and efficiently communicate the value of our product to key stakeholders (e.g. payers)?? What concerns about the product will payers have at launch? What options do we have to address these concerns? Source: Simon-Kucher & Partners. 16
17 Output example: Value message matrix Simon-Kucher uses the value message matrix to present the different rating criteria for each message in order to draw conclusions and view the overall success of the payer value story. Value message matrix Importance of value message High Low Evidence needed (Important for coverage/reimbursem ent but not believable improvement in evidence needed!) Lower Priority (Not as believable, and has little impact on coverage / reimbursement) Competitive advantage (Well-supported, believable, and has a positive impact on coverage / reimbursement) Nice-to-have (Respondents find value message credible, but little coverage / reimbursement impact) Uniqueness Each value message is graphed in the matrix as a dot. The size of the dot indicates the uniqueness of the value message. Other options deliver the same Value message matrices can be created for specific payer segments No competitor can deliver this Low Credibility of value message High Source: Simon-Kucher & Partners 17
18 Comprehensive approaches to evaluating the pricing opportunities In the US, multiple methodologies across stakeholder groups will ensure results are validated by both payers and robust quantitative research. Value story impact on pricing Pricing strategy development Comprehensive revenue analysis Aggregation of data Pricing opportunities Identify key opportunities and challenges for coverage across price points, including e.g. differences in cost-sharing implications of Commercial, Medicare Part D, and Medicaid Assess physician price sensitivity and willingness to prescribe under various access scenarios and price points Media scrutiny Identify potential risks of negative media attention at various price levels to minimize risk to the overall P&MA strategy Source: Simon-Kucher & Partners; Forbes Online; New York Magazine 18
19 Data from payers and physicians are combined to generate aggregate sensitivity curves A revenue function for will influence decision-making among pricing strategy options. Conceptual % of lives 50% 25% 0% 1. Payer / hospital access Payer management by pricing scenario 100% 75% 50% 25% 0% 81% 87% 19% 13% 13% 12% 2. Physician prescribing 33% 27% 10% 77% 20% 68% Price 1 Price 2 Price 3 Price 4 18% Peer-to-peer review PA to label Minimal management Physician prescribing by price / copay scenario % of patients 7% Price 1 Price 2 Price 3 Price 4 60% 40% 20% 3. Product utilization Aggregate utilization (including management and price sensitivity) 0% Price 1 Price 2 Price 3 Price 4 4. Revenue functions Revenue maximization Price 1 Price 2 Price 3 Price 4 Revenue = price * volume Index 100 = maximum revenue Simon-Kucher uses robust decision simulation exercises to generate the input data for these exercises (with both physicians and payers). Source: Simon-Kucher & Partners 19
20 Outcome example from EU payer research: Where will restrictions/loss of reimbursement occur? Expected price-restriction relationships European countries Conceptual France Germany Italy Spain Reimbursement exclusion P2 Severe restriction A P4 Therapy Advice U P3 Reimbursement exclusion P7 Reimbursement exclusion P9 Note: Restrictions would be described in detail, (i.e. restricted to use only in specific patient populations, ) Price Restriction T P1 Restriction W Restriction V P6 P5 Restriction X P8 Innovative access schemes and back of the envelope cost/ QALY calculations will be explored as relevant per market Restriction threshold by payers Reimbursement or severe restrictions/coverage threshold by payers Thresholds derived from both primary research and implications of national P&R systems (i.e. expected ASMR score in France and related implications for P&R opportunities) Source: Simon-Kucher & Partners 20
21 Agenda Why worry about P&MA during development? What factors should be considered and when? Evaluating the risk vs reward trade-off 21
22 When evaluating investment options, changes in the perceived value of a product can be quantified Additional perceived value provided by additional evidence Value What is the cost? What would be the impact of non-successful study? Product value Sub-population data Outcome study Health economic model Source: Simon-Kucher & Partners 22
23 Measuring the impact of investment in additional data Does the additional data. Investment cost Investment impact Increase the achievable price? Reduce access barriers? Increase product uptake? Source: Simon-Kucher & Partners 23
24 Can the impact of the additional data be measured within the global sales forecast? 1,000,000 Global sales forecast Annual sales (m ) 750, , ,000 - Year Source: Simon-Kucher & Partners 24
25 Thank you Boston office One Canal Park Cambridge, MA 02141, USA Tel
THE BIG DIGITAL FAIL Why Only 1 in 4 Companies Achieve Topline Growth with Digitalization
THE BIG DIGITAL FAIL Why Only 1 in 4 Companies Achieve Topline Growth with Digitalization Results & Insights of the Global Pricing & Sales Study 2017 In collaboration with: The Center for Pricing at Simon
More informationJosh Bloom Partner Simon-Kucher
Josh Bloom Partner Simon-Kucher 1 Licensing Model Transitions Simon-Kucher and Partners 2016 Silicon Valley Office 100 View Street Mountain View, CA 94041 Cell: (650) 691 3315 Joshua.Bloom@simon-kucher.com
More informationWHY 97% OF ALL PRICE INCREASES FAIL and what your company needs to do different this year
WHY 97% OF ALL PRICE INCREASES FAIL and what your company needs to do different this year Image: colourbox.com Philip W. Daus October 2017 www.simon-kucher.com It s that time of the year again. Companies
More information9 Must-Haves for a Successful Implementation of a Pricing Strategy
9 Must-Haves for a Successful Implementation of a Pricing Strategy Arjen Brasz Nina Hoette March 2017 www.simon-kucher.com 1 Successful Price Strategy Implementation in B2B No other lever has more impact
More informationThe Emerging Markets Acceleration Program and Globalization Readiness Index. Capturing Breakthrough Growth in Emerging Markets
The Emerging Markets Acceleration Program and Globalization Readiness Index Capturing Breakthrough Growth in Emerging Markets The Boston Consulting Group (BCG) is a global management consulting firm and
More informationChina Luxury Survey 2013
SIMON-KUCHER & PARTNERS Luxury Goods China Luxury Survey 2013 Changing tides: catching the next profit wave The results presented in this document cover all the brands surveyed. Brand-specific results
More informationMonetizing Digitalization Boosting revenue and profits in a digital world
Monetizing Digitalization Boosting revenue and profits in a digital world www.simon-kucher.com Contents Digitalization The big transformer Digitalization is Pitfalls of digitalization and how to become
More informationThe Rise of the Female Economy in B2B a source of UK competitiveness
A.T. Kearney in association with the CBI The Rise of the Female Economy in B2B a source of UK competitiveness January 29 th 2014 Agenda Introduction Part 1: The six drivers: Why is the female economy important
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationHelping unlock growth opportunities worldwide
Helping unlock growth opportunities worldwide A trusted partner for high-stakes decisions While scientific and technological advances fuel new business opportunities, the cost of bringing each new product
More informationJordi Aparici Market Intelligence Consultant
Jordi Aparici Market Intelligence Consultant Helping pharma companies make robust decisions based on market, competitors and patient knowledge Market Intelligence Strategy Marketing Market Research Data
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationHealthcare.
Healthcare www.stantonchase.com Stanton Chase is a leader in executive search and leadership consulting with a global footprint, local expertise, and extensive experience across numerous industries and
More informationStaying on the Leading Edge
Human Resources Staying on the Leading Edge Five important qualities for aspiring chief human resources officers So you want to be a CHRO. That s an admirable goal, but keep in mind that the responsibilities
More informationENGINEERED LUMBER TRENDS EUROPE VS NORTH AMERICA April 7 th 2016 Atlanta US
EUROPE VS NORTH AMERICA April 7 th 2016 Atlanta US AGENDA Brief introduction to Pöyry Engineered Lumber Trends 2 BRIEF INTRODUCTION TO PÖYRY 3 PÖYRY CONSULTING AND ENGINEERING EXPERTS Pöyry is an international
More informationBusiness transformation and the role of change agents
Kuwait Change Management Conference Business transformation and the role of change agents Presentation Kuwait, December 2017 Eduard Gracia Principal A.T. Kearney Every major business transformation is
More informationPrice a Neglected Generator of Profit
Price a Neglected Generator of Profit 5th International Controller Conference in Croatia Zagreb, November 14, 2017 Richard Zinoecker Managing Partner CEE Office Warsaw ul. Wołoska 9 02-583 Warszawa, Polska
More informationWHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs
Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends
More informationRetail Banking: A Wealth of Opportunity for Retailers?
Retail Banking: A Wealth of Opportunity for Retailers? The retail banking sector, facing unprecedented change, offers an exciting opportunity for new entrants and particularly retailers if they ask the
More informationAirline Employer Branding: How to measure the Unmeasurable
Airline Employer Branding: How to measure the Unmeasurable Hans Nilsson Global Sector Leader Aviation & Aerospace Partner www.stantonchase.com The global airline industry has changed significantly during
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationFuture of Retail Banking in Romania
What do Banking Executives expect to happen Future of Retail Banking in Romania Survey Summary May 2014 Bucharest Agenda Executive summary "Future of Retail Banking in Romania" survey Y8YbtcQklln07kHyQ1
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationForecasting strategies and success factors. March 21, 2017
Forecasting strategies and success factors March 21, 2017 Today s presenters Speakers Chris Reinholz Senior Manager, Transaction Advisory Services Ernst & Young LLP George Carey Executive Director, Transaction
More informationThe Top Healthcare Compensation Issues for 2016
TRENDS & ISSUES The Top Healthcare Compensation Issues for 2016 AUTHORS Steve Sullivan Principal Transformation in healthcare is an extended journey over uncharted waters, featuring untested business strategies,
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationISM Travel & Events. Graham Crawshaw MCIPS Director of Content June 2017
ISM Travel & Events Graham Crawshaw MCIPS Director of Content June 2017 Best in Class: What does good look like? Global Network of Procurement Professionals 10,000+ active participants 70 countries represented
More information7 Pivotal HR competencies for global business in 2017
Your Leadership Partner 7 Pivotal HR competencies for global business in 2017 Karen Fogh-Andersen, Managing Partner Stanton Chase Copenhagen, Denmark March 2017 www.stantonchase.com How companies need
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationChallenging Stakeholders
5 Ways to Engage Challenging Stakeholders Graham Crawshaw MCIPS Director of Content December 2016 Not familiar with CASME? 40 benchmarking reports and procurement guides published each year A network of
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More information2 A&O A career in law
A career in law 2 A&O A career in law Allen & Overy LLP 2018 3 Poppy Kgwadi Candidate Attorney poppy.kgwadi@allenovery.com A&O has exposed me to a vast array of groundbreaking work in the South African
More informationIntellectual Capital. On Demand.
Intellectual Capital. On Demand. A unique approach to consulting. RGP is made up of proven problem solvers accomplished professionals who give you the help you need, when you need it, how you need it.
More informationCommercial Pricing and Contracting 101
Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai
More informationGaining and Sustaining Competitive Advantage
Fourth Edition Gaining and Sustaining Competitive Advantage Jay B. Barney The Ohio State University Boston Columbus Indianapolis New York San Francisco Upper Saddle River Amsterdam Cape Town Dubai London
More informationImpact of Patient Engagement on Project Valuation
Impact of Patient Engagement on Project Valuation Bennett Levitan, MD-PhD Epidemiology, Janssen Research and Development CTTI Patient Groups & Clinical Trials Expert Meeting January 22, 2015 2 Disclosures
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationTaking Control of Your Fuzzy
Taking Control of Your Fuzzy Front End MassMedic Presentation September 22, 2010 Sanjeev Wadhwani Project Management Consultant Integrated Project Management Company, Inc. Sanjeev Wadhwani Project Manager
More informationA.T. Kearney Aerospace & Defense Services. Creating tangible and lasting results in Aerospace & Defense
A.T. Kearney Aerospace & Defense Services Creating tangible and lasting results in Aerospace & Defense A.T. Kearney s Scope of Expertise A.T. KEARNEY IS A GLOBAL MANAGEMENT CONSULTING FIRM THAT uses strategic
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationGENERAL PAYER CONSIDERATIONS FOR NEW HEALTH TECHNOLOGIES (INCLUDING DIAGNOSTICS)
FORUM Payer perspectives and actions impacting diagnostics in the US and Europe Eric Faulkner, MPH Director, Quintiles Global Market Access Consulting; Executive Director, Genomics Biotech Emerging Medical
More informationOpportunities for Action in Financial Services. Refocusing on Costs
Opportunities for Action in Financial Services Refocusing on Costs Refocusing on Costs Thanks to rapid economic expansion and widespread industry consolidation, banks have grown dramatically during the
More informationLeadership Transitions: Differences Across Leadership Levels
25 June 2013 Leadership Transitions: Differences Across Leadership Levels Joy F. Hazucha The Korn/Ferry Leadership and Talent Consulting family Mission Better leaders, Better world Vision Premier global
More informationDisclosure of Clinical Trial Data in EU
Disclosure of Clinical Trial Data in EU What are the implications of the new rules? Elisabethann Wright 13 May 2015 Current framework in the EU There are currently three bases on which clinical data can
More informationValue Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool
Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool Kati Copley-Merriman, MBA, MS Vice President, Regulatory and Health Outcomes Strategy RTI Health Solutions Stephanie Barrows,
More informationBiotherapeutic product characterization to support accelerated process development
Biotherapeutic product characterization to support accelerated process development Kyle Zingaro, Ph.D. Alexion Pharmaceuticals 2015 Biomanufacturing Technology Summit June 25, 2015 Our Mission: Treating
More informationPayNet UK Salary Tracker: What is the real cost of living for UK employees today?
PayNet UK Salary Tracker: What is the real cost of living for UK employees today? Overview Hay Group s quarterly PayNet UK Salary Tracker looks at how employees pay compares with a range of key economic
More informationThe Price of Global. Drug Pricing Strategies to Balance. Patient Access and the Funding of
The Price of Global Health Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation Second Edition ED SCHOONVELD GOWER Contents List offigures ListofTables List of Abbreviations
More informationValuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia
Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion Venture Valuation Independent assessment
More informationHay Group Spectrum. The next generation HR solution
Hay Group Spectrum The next generation HR solution Today, you can t afford to have anything less than an integrated approach to HR. An approach that delivers real insights to strategic decision-making.
More informationPutting the Wholesaler in the Driver s Seat. Best practices from the retail industry to improve profitability and gain competitive advantage
Putting the Wholesaler in the Driver s Seat Best practices from the retail industry to improve profitability and gain competitive advantage Wholesalers are more than supply chain intermediaries controlling
More informationPharmaceutical innovation and pricing regulation
Pharmaceutical innovation and pricing regulation A study prepared for Novartis by ESMT Competition Analysis Dr. Hans W. Friederiszick Prag, 13 January 2011 Pharmaceutical Innovation and Pricing Regulation
More informationInspiring Procurement Excellence PASIA World Conference. November 2016
Inspiring Procurement Excellence PASIA World Conference November 2016 Jess is responsible for developing new business and bringing prospective members within the Asia Pacific region into the CASME community.
More informationDigital Leadership: Will the Chief Information Officer Role Disappear?
Technology Officer Digital Leadership: Will the Chief Information Officer Role Disappear? Years ago, chief information officers (CIOs) occupied a key role within the business world. They were seen as the
More informationDeveloping Strong Partnerships to Ensure Success With Global Medical Device Trials. 23-February-2017, OCT Burlingame
Developing Strong Partnerships to Ensure Success With Global Medical Device Trials 23-February-2017, OCT Burlingame www.genae.com With you, for you Agenda 01 02 Identify the core group of stakeholders
More informationOur Practice Group Public procurement law
Our Practice Group Public procurement law Allen & Overy in Germany 2018 2 Our Practice Group Public procurement law Allen & Overy in Germany 2018 Public procurement law Many contracting authorities and
More informationEngaging for Results. Opportunities for Action in Financial Services
Engaging for Results 6/26/03 9:59 AM Page 1 Opportunities for Action in Financial Services Engaging for Results Engaging for Results How many of your organization s employees would honestly describe their
More informationOpportunities for Action in Industrial Goods. Making E-Procurement Real Now
Making E-Procurement 1/29/01 1:38 PM Page 1 Opportunities for Action in Industrial Goods Making E-Procurement Real Now Making E-Procurement Real Now Electronic procurement is supposed to be the slam dunk
More informationGovernance Watch Webcast #1: Best Practices in Board Succession Planning
Governance Watch Webcast #1: Best Practices in Board Succession Planning In the ever-evolving market, boards must carefully consider how they will both lead and adapt along with their organizations. In
More informationehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014
ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014 Health care is in the middle of a perfect storm Changing demographics Unmet needs
More informationOpportunities in the Health Care Practice at Analysis Group
Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice
More informationMedical Affairs for Modern Pharma New Challenges & Competencies
2-Day Course Medical Affairs for Modern Pharma New Challenges & Competencies Learn how medical affairs can enhance the commercial success of pharma brands with market insight generation, brand value definition,
More informationTrinity ConTRact: Cornerstone Projects in Contracting Strategy
Trinity ConTRact: Cornerstone Projects in Contracting Strategy With mounting external pressures limiting access and tightening reimbursement, effective contracting is critical to the commercial success
More informationThe Five Things I Wish I Had Known When I Was Promoted to the C-Suite
The Five Things I Wish I Had Known When I Was Promoted to the C-Suite I wish I had known then what I know now. The Five Things I Wish I Had Known When I Was Promoted to the C-Suite I wish I had known then
More informationRWE Market Impact on Medicines: A Lens for Pharma
EXECUTIVE SUMMARY RWE Market Impact on Medicines: A Lens for Pharma An international comparison of the use and impact of Real World Evidence The pharmaceutical industry s increasing focus on RWE reflects
More informationConvergence and difference in HTA approaches in UK, Germany and France: reflections on recent and proposed changes
Convergence and difference in HTA approaches in UK, Germany and France: reflections on recent and proposed changes Professor Ron Akehurst School of Health and Related Research Content of Talk During this
More informationFinancial Modeling and Excel Courses
Knowledge Skills Conduct Financial Modeling and Excel Courses Both instructors were brilliant - friendly, approachable, clear and able to answer all questions. Emily Roberts, Deutsche Bank Bangkok Casablanca
More informationGuide to becoming a self-employed lawyer in Australia
Guide to becoming a self-employed lawyer in Australia Contents Legal consulting a new way of working 3 Peerpoint the right choice for you? 4 The basics of self-employment 5 Setting up and running an ILP
More informationOpportunities for Action in Consumer Markets. Myths and Realities of On-Line Retailing
Opportunities for Action in Consumer Markets Myths and Realities of On-Line Retailing Myths and Realities of On-Line Retailing Business success is grounded in the ability to understand where the economy
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationASSISTANCE AND ASSESSMENT:
ASSISTANCE AND ASSESSMENT: HELPING PHARMA MEASURE AND MAXIMIZE MEDICAL AFFAIRS PERFORMANCE Gary Kaplan, M.A., Vice President, Medical Affairs Research, ClinicalSCORE Effective Medical Affairs More Critical
More informationDigital Transformation in the Industrial Sector
Digital Transformation in the Industrial Sector Defining new strategies and priorities in a changing world After the economic challenges of the past decade, industrial companies realized an important truism:
More informationISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research
ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research Pascale Boyer Barresi, CFA Business Analysis, BD&L September 2014
More informationWarehousing: Charting the Way to a Winning Strategy
Warehousing: Charting the Way to a Winning Strategy Strong headwinds are challenging how companies operate their warehouses. Successful navigation hinges on optimizing capacity, improving utilization,
More informationFalse Self-Employment and Illegal Use of Temporary Workers
False Self-Employment and Illegal Use of Temporary Workers IT-based solution for fast and convenient assessment of individual cases Risks involved in the use of external personnel not to be underestimated
More informationUtilize Real World Data to Optimize Patient Savings Programs. Mason Tenaglia Vice President, IMS Institute, Payer and Managed Care Insights
Utilize Real World Data to Optimize Patient Savings Programs Mason Tenaglia Vice President, IMS Institute, Payer and Managed Care Insights September 2018 0 Today we will answer three major questions 1.
More informationICA Demand Curve Development:
ICA Demand Curve Development: Proposed Approach for Ontario PRESENTED TO Market Renewal Incremental Capacity Auction Stakeholder Group PRESENTED BY Kathleen Spees Johannes Pfeifenberger Yingxia Yang John
More informationBoards and Board Evaluations: A Missed Opportunity Erik P.M. Vermeulen
Boards and Board Evaluations: A Missed Opportunity Erik P.M. Vermeulen Shareholders Legal/Moral Owners = Corporate ACCOUNTABILITY Board of Directors CEO/Executives Staff EMPOWERMENT Governance Compliance
More informationphysician Developing Accelerate the development of those responsible for transforming your business
Developing physician Accelerate the development of those responsible for transforming your business Physicians across the country are increasingly being asked not only to serve in their traditional role
More informationPrinciples of Pharmaceutical Marketing for Non-Marketing Functions
2-Day Course Principles of Pharmaceutical Marketing for Non-Marketing Functions Understand the marketing principles that determine a pharmaceutical s commercial success - Learn how your function can contribute
More informationDoing Life Science Business in Germany Illinois Life Sciences & Technology Park Skokie, Illinois June 1, 2012
Chris Schmidt - istockphoto Illinois Life Sciences & Technology Park Skokie, Illinois June 1, 2012 Media Acclaim for a Flourishing Economy Strong economic performance Sound financial management The Economist,
More informationEvaluating the Chief Executive Off i c e r. Copyright 1998 Korn/Ferry International
Evaluating the Chief Executive Off i c e r Copyright 1998 Korn/Ferry International 2 Table of Contents The Growth in CEO Evaluations...6 The Benefits of a CEO Evaluation...6 A Step-by-Step Guide to CEO
More informationDo We Need Medical Affairs?
Do We Need Medical Affairs? Dr Richard Nieman Head of Medical Affairs, Asia Bayer Healthcare Pharmaceuticals Global R&D Center, Beijing, China May 17, 2011 Biographical Sketch of Dr Richard Nieman Dr Richard
More informationThe Path to Clinical Enterprise Maturity DEVELOPING A CLINICALLY INTEGRATED NETWORK
The Path to Clinical Enterprise Maturity DEVELOPING A CLINICALLY INTEGRATED NETWORK dhgllp.com/healthcare Kevin Locke PRINCIPAL Kevin.Locke@dhgllp.com 330.606.4699 Michael Strilesky SENIOR MANAGER Michael.Strilesky@dhgllp.com
More informationConsumer Products & Services.
Consumer Products & Services www.stantonchase.com Stanton Chase is a leader in executive management and board search with global reach, local expertise, and extensive experience across numerous industries
More informationBiosimilars are interchangeable with their reference products under the supervision of a health care person.
EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES? Tomas Tesar, PharmD, PhD, MBA, MSc Member of
More informationInvestor Update. Jefferies Global Healthcare Conference June Because people depend on us
Investor Update Jefferies Global Healthcare Conference June 2014 Because people depend on us Forward-looking statement This presentation and information communicated verbally to you may contain certain
More informationUnderstanding the Role of the Chief Strategy Officer
Understanding the Role of the Chief Strategy Officer The Boston Consulting Group (BCG) is a global management consulting firm and the world s leading advisor on business strategy. We partner with clients
More informationPerspectives. The Hardball Manifesto
Perspectives The Hardball Manifesto The Hardball Manifesto This Perspective is adapted from the authors new book, Hardball: Are You Playing to Play or Playing to Win? (Harvard Business School Press, October
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationPerspectives. The Hotel Clerk
Perspectives The Hotel Clerk 2 BCG PERSPECTIVES The Hotel Clerk What a piece of work is a man! How noble in reason! How infinite in faculty! In form and moving how express and admirable! from William Shakespeare,
More informationIndustrial Goods Five Leadership Issues Worthy of Board and Executive Attention
Industrial Goods Five Leadership Issues Worthy of Board and Executive Attention 2 Introduction The industrial goods sector, including manufacturing of electric goods and electronic systems, as well as
More informationUsing Shareholder Value Analysis for Acquisitions
VOLUME I, ISSUE 2 Using Shareholder Value Analysis for Acquisitions We are pleased to bring to you the latest in our Executive Insights newsletter series. Through our work in implementing shareholder value
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationThe Challenge of Pricing Combination Therapies
The Challenge of Pricing Combination Therapies By David Greber and Srikant Vaidyanathan The role of combination therapies in medicine continues to grow. For the treatment of HIV/AIDS, cancer, and hepatitis
More informationOpportunities for Action in Information Technology. Clusters and Nuggets: Mastering Postmerger IT Integration
Opportunities for Action in Information Technology Clusters and Nuggets: Mastering Postmerger IT Integration Clusters and Nuggets: Mastering Postmerger IT Integration In an age when corporate mergers are
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationGlobal Model Workstation
Global Model Workstation The Oxford Economics Global Model Workstation provides a rigorous and consistent structure for forecasting and testing scenarios. Because our economic and industry models are fully
More information